论文部分内容阅读
目的 :研究血清类胰岛素生长因子Ⅰ (Insulin -likegrowthfactor - 1,IGF -Ⅰ )与前列腺癌的关系。方法 :采用免疫放射量度分析法 (IRMA)测定 30例前列腺癌患者血清IGF -Ⅰ水平 ,并以 30例健康组以及30例良性前列腺增生 (BPH)患者作对照。结果 :前列腺癌组血清IGF -Ⅰ含量显著上升 (148± 49.6 μg/L) ,与BPH(91.0± 32 .8μg/L)及健康组 (10 5± 2 5 .6 μg/L)差异有显著性 (均为P <0 .0 0 1)。BPH组血清IGF -Ⅰ含量与健康组比较差异无显著性 (P >0 .0 5 ) ;前列腺癌患者各期血清IGF -Ⅰ含量比较差异无显著性 (P >0 .0 5 ) ;IGF-Ⅰ与BPH无关 ,其水平升高增加前列腺癌的危险性 ,与健康组相比较 ,高IGF -Ⅰ水平患者前列腺癌的相对危险度 (OR)为 11.2 3,95 % ,可信区间为 3.0 9～ 40 .7,前列腺癌患者与健康组之间有统计学意义 (P <0 .0 0 1)。结论 :提示IGF -Ⅰ可能增加患前列腺癌的危险性。
Objective: To study the relationship between serum insulin-like growth factor-1 (IGF-I) and prostate cancer. METHODS: Serum IGF-I levels in 30 patients with prostate cancer were measured by immunoradiometric analysis (IRMA) and compared with 30 healthy subjects and 30 patients with benign prostatic hyperplasia (BPH). Results: Serum IGF-I level in prostate cancer group increased significantly (148±49.6 μg/L), and was significantly different from BPH (91.0± 32.8 μg/L) and healthy group (105±25.6 μg/L). Sex (all P <0. 0 0 1). The serum IGF-I levels in the BPH group had no significant difference with the healthy group (P > 0.05). There was no significant difference in serum IGF-I levels between the prostate cancer patients (P > 0.05); IGF- I and BPH have nothing to do with increasing the level of prostate cancer and the risk of prostate cancer. Compared with the healthy group, the relative risk (OR) of prostate cancer in patients with high IGF-I level was 11.23, 95%, with a confidence interval of 3.09. ~ 40.7, statistically significant between prostate cancer patients and healthy patients (P < 0.01). Conclusion: It is suggested that IGF-I may increase the risk of prostate cancer.